UK rebate mechanism could force market withdrawals, warns BGMA
This article originally appeared in our sister publication Generics Bulletin
A UK rebate mechanism designed to increase access to new treatments and promote affordability “could actually be denying the NHS billions of pounds of annual savings due to the impact it is having on branded generics and biosimilars”, according to the BGMA.
